On Thursday, Eli Lilly released the first batch of late-stage data for its next-generation diet drug retatrutide. The drug's mechanism of action is different from existing injections and appears to be more effective because it targets three different appetite-regulating hormones simultaneously, while Wegovy and Zepbound target only one or two.

On Thursday, Eli Lilly released the first batch of late-stage data for its next-generation diet drug retatrutide. The drug's mechanism of action is different from existing injections and appears to be more effective because it targets three different appetite-regulating hormones simultaneously, while Wegovy and Zepbound target only one or two.